Lectin mediated biorecognition as a novel strategy for targeted delivery to bladder cancer

Journal of Urology

Volumn 186, Issue 4, 2011, Pages 1481-1488

  Neutsch, Lukas ^a   Plattner, Verena E ^a   Polster Wildhofen, Sonja ^b   Zidar, Agnes ^a   Chott, Andreas ^b   Borchard, Gerrit ^c   Zechner, Othmar ^b   Gabor, Franz ^a   Wirth, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b WILHELMINEN HOSPITAL   (Austria)

^c UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

administration; carcinoma; drug delivery systems; intravesical; lectins; urinary bladder

Indexed keywords

CARBOHYDRATE; CARBOHYDRATE BINDING PROTEIN; LECTIN; MONENSIN; PEANUT AGGLUTININ; WHEAT GERM AGGLUTININ;

ARTICLE; BIORECOGNITION; BLADDER CANCER; CANCER THERAPY; CELL ADHESION; CELL INTERACTION; CELL SPECIFICITY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TUMOR LEVEL; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; FLUOROMETRY; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IC 50; INTERNALIZATION; INTRAVESICAL DRUG ADMINISTRATION; MOLECULAR INTERACTION; PRIORITY JOURNAL;

ADMINISTRATION, INTRAVESICAL; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; DRUG DELIVERY SYSTEMS; FLOW CYTOMETRY; HUMANS; MICROSCOPY, FLUORESCENCE; MONENSIN; PLANT LECTINS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS; UROTHELIUM;

EID: 80052754008     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.05.040     Document Type: Article

References (28)

1. M.C. Hall, S.S. Chang, and G. Dalbagni Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update J Urol 178 2007 2314
2. B.W.G. van Rhijn, M. Burger, and Y. Lotan Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy Eur Urol 56 2009 430
3. J.E. Montie, P.E. Clark, and M.A. Eisenberger Bladder cancer J Natl Comp Cancer Netw 7 2009 8
4. K.D. Sievert, B. Amend, and U. Nagele Economic aspects of bladder cancer: what are the benefits and costs? World J Urol 27 2009 295
5. S.P. Lerner, H.B. Grossman, and E.M. Messing BCAN think tank session 3: prevention of bladder cancer Urol Oncol 28 2010 338
6. A. Witjes, and K. Hendricksen Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical review of currently available drugs, treatment schedules, and long-term results Eur Urol 53 2008 45
7. M.H.A. Hussain, D.P. Wood, and D.F. Bajorin Bladder cancer: narrowing the gap between evidence and practice J Clin Oncol 27 2009 5680
8. J. Dobruch, and H. Herr Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection? BJU Int 104 2009 170
9. M.P. Koya, M.A. Simon, and M.S. Soloway Complications of intravesical therapy for urothelial cancer of the bladder J Urol 175 2006 2004
10. J.P.B. Gasion, and J.F.J. Cruz Improving efficacy of intravesical chemotherapy Eur Urol 50 2006 225
11. J.L.S. Au, R.A. Badalament, and M.G. Wientjes Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial J Natl Cancer Inst 93 2001 597
12. Z. Shen, T. Shen, and M.G. Wientjes Intravesical treatments of bladder cancer: review Pharmacol Res 25 2008 1500
13. S.M. Di Stasi, A. Giannantoni, and R.L. Stephen Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study J Urol 170 2003 777
14. E. Bilensoy, C. Sarisozen, and G. Esendagli Intravesical cationic nanoparticles of chitosan and polycaprolactone for the delivery of mitomycin C to bladder tumors Int J Pharmacol 371 2009 170
15. C. Le Visage, N. Rioux-Leclercq, and M. Haller Efficacy of paclitaxel released from bio-adhesive polymer microspheres on model superficial bladder cancer J Urol 171 2004 1324
16. Z. Lu, T.K. Yeh, and M. Tsai Paclitaxel-loaded gelatin nanoparticles for intravesical bladder cancer therapy Clin Cancer Res 10 2004 7677
17. O.C. Farokhzad, J.D. Dimitrakov, and J.M. Karp Drug delivery systems in urologygetting 'smarter' Urology 68 2006 463
18. J.H. Pinthus, A. Bogaards, and R. Weersink Photodynamic therapy for urological malignancies: past to current approaches J Urol 175 2006 1201
19. C. Ohyama Glycosylation in bladder cancer Int J Clin Oncol 13 2008 308
20. M. Liebert, D. Gebhardt, and C. Wood Urothelial differentiation and bladder cancer Adv Exp Med Biol 462 1999 437
21. M.E. Kreft, R. Romih, and M. Kreft Endocytotic activity of bladder superficial urothelial cells is inversely related to their differentiation stage Differentiation 77 2009 48
22. B.K. Dhakal, R.R. Kulesus, and M.A. Mulvey Mechanisms and consequences of bladder cell invasion by uropathogenic Escherichia coli Eur J Clin Invest 38 2008 2
23. S.M.P. Yi, R.E. Harson, and J. Zabner Lectin binding and endocytosis at the apical surface of human airway epithelia Gene Ther 8 2001 1826
24. V.E. Plattner, M. Wagner, and G. Ratzinger Targeted drug delivery: binding and uptake of plant lectins using human 5637 bladder cancer cells Eur J Pharmacol Biopharmacol 70 2008 572
25. D.E. Neal, R.G. Charlton, and M.K. Bennett Histochemical study of lectin binding in neoplastic and non-neoplastic urothelium Br J Urol 60 1987 399
26. S.T. Truschel, E. Wang, and W.G. Ruiz Stretch-regulated exocytosis/endocytosis in bladder umbrella cells Mol Biol Cell 13 2002 830
27. P. Khandelwal, W.G. Ruiz, and G. Apodaca Compensatory endocytosis in bladder umbrella cells occurs through an integrin-regulated and RhoA- and dynamin-dependent pathway EMBO J 29 2010 1961
28. F. Gabor, E. Bogner, and A. Weissenboeck The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery Adv Drug Deliv Rev 56 2004 459